Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable to TACE By Ogkologos - January 15, 2025 828 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMERALD-1 and LEAP-012 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR New Treatment Combinations Slow Progression of Prostate Cancer and Stomach and... February 5, 2024 Utility of Genomic Profiling Use for Targeted Therapy in a Phase... May 6, 2025 EMA Recommends Granting a Marketing Authorisation for Generic Enzalutamide August 9, 2024 EMA Publishes Guidance to Provide Key Methods and Good Regulatory Practices... November 8, 2021 Load more HOT NEWS FDA Approves Crizotinib for ALK-positive Inflammatory Myofibroblastic Tumour Women in science: Cancer research pioneers – part 2 Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens... For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment Target
